Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

Time to first occurrence of any fatal or non-fatal MI

This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter
 study in subjects recently hospitalized for ACS and with the appropriate genetic profile.
 Subjects will provide informed consent before any study-specific procedures are performed. A
 separate informed consent will be allowed for an initial pre-screening genetic testing.
 Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic
 testing as required. Subject enrollment may begin in the hospital and will continue following
 release from the hospital or may begin following release from hospital. Screening procedures
 may be performed at the time of the index ACS event or anytime thereafter, with the condition
 that randomization must occur within the mandated window (up to12 weeks after the index
 event). Subjects will be assessed based on their medical history. Those who are likely to
 qualify will undergo Genotype Assay testing to evaluate genetic determination for the
 presence of AA genotype.